Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 40
- Registration Number
- NCT00199095
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 225
- Registration Number
- NCT00199056
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 43
- Registration Number
- NCT00195000
- Locations
- 🇺🇸
Weill Medcial College of Cornell University, New York, New York, United States
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 87
- Registration Number
- NCT00195104
- Locations
- 🇺🇸
Weill Medcial College of Cornell University, New York, New York, United States
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 80
- Registration Number
- NCT00180128
- Locations
- 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT00187122
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 498
- Registration Number
- NCT00165178
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 920
- Registration Number
- NCT00151242
- Locations
- 🇩🇪
Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany
🇦🇹Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria
🇩🇪Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 500
- Registration Number
- NCT00151255
- Locations
- 🇦🇹
Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇩🇪Medical Department I, Hospital of Bremen-Mitte, Bremen, Germany
🇩🇪Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.